Formycon Achieves Strong Revenue Growth and Operational Progress in Q1 2026

Formycon AG has reported significant operational advancements and revenue growth for the first quarter of 2026. The company launched the FYB203 biosimilar in Europe, expanding its portfolio to three in-house developed products. FYB206, a Keytruda® biosimilar, has reached a clinical milestone, enhancing Formycon's stature among pembrolizumab developers. The company's financial growth is evidenced by a revenue increase to €13.1 million from €5.3 million in Q1 2025, mainly driven by milestone payments and biosimilar commercialization. Formycon’s strategic aim, "FYB4Growth," focuses on geographic and portfolio diversification, promoting sustainable value creation.

Adjustments to EBITDA show an improvement, with the first-quarter figure at €-1.7 million compared to €-13.2 million in the same period last year. This trajectory is supported by reduced R&D and structure costs. Formycon projects significant revenue contributions from FYB202 and continued investment in its pipeline. Overall, company guidance for 2026 anticipates revenues between €60.0 to €70.0 million, showcasing a robust foundation for further growth in the competitive biosimilar market.